Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria

Diabetologia

Volumn 48, Issue 1, 2005, Pages 156-163

  Gaede P ^a   Hildebrandt, P ^b   Hess, G ^c,d   Parving, H H ^a,e   Pedersen, O ^a,e  

^a STENO DIABETES CENTER   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

Cardiovascular disease; Heart failure; Microalbuminuria; Multifactorial intervention trial; Natriuretic peptide; Risk factors; Type 2 diabetes

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; MARKER; UNCLASSIFIED DRUG;

ADULT; AMPUTATION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG TARGETING; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PATIENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK REDUCTION; STROKE;

ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; SMOKING; TIME FACTORS;

EID: 12944320330     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1607-0     Document Type: Article

References (19)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444
2. de Lemos JA, McGuire DK, Drazner MH (2003) B-Type natriuretic peptide in cardiovascular disease. Lancet 362:316-322
3. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J (2001) Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310:193-197
4. Motwani JG, McAlpine H, Kennedy N, Struthers AD (1993) Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 341:1109-1113
5. Latini R, Masson S, Anand I et al (2002) Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106:2454-2458
6. Johnson W, Omland T, Hall C et al (2002) Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39:1623-1629
7. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126-1130
8. Murdoch DR, McDonagh TA, Byrne J et al (1999) Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138:1126-1132
9. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393
10. Yeo KTJ, Wu AHB, Apple FS et al (2003) Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338:107-115
11. Devereux RB, Reichek N (1977) Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 55:613-618
12. Brøchner-Mortensen J, Tougaard L, Fynboe C, Thomsen HG (1976) Individual determination of glomerular filtration rate from plasma creatinine. Scand J Clin Lab Invest 36:389-393
13. Richards AM, Nicholls MG, Yandle TG et al (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97:1921-1929
14. Groenning BA, Nilsson JC, Sondergaard L et al (2002) Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am Heart J 143:923-929
15. de Lemos JA, Morrow DA, Bentley JH et al (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345:1014-1021
16. Raymond I, Groenning BA, Hildebrandt PR et al (2003) The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89:745-751
17. Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New Engl J Med 350:655-663
18. Yano Y, Katsuki A, Gabazza EC et al (1999) Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 84:2353-2356
19. Asakawa H, Fukui T, Tokunaga K, Kawakami F (2002) Plasma brain natriuretic peptide levels in normotensive type 2 diabetic patients without cardiac disease and macroalbuminuria. J Diabetes Complicat 16:209-213